Oregon's Araceli Biosciences wraps $4.5M convertible round to fund commercial push
What's the deal? Tigard, Oregon-based Araceli Biosciences is closing a $4.5 million convertible financing to fund its commercial execution, according to a November 2026 filing. The startup makes high-content imaging instruments and AI-analysis software for drug discovery.
Why now? The round follows an $11.2 million seed financing closed in April 2025, which combined $7.2 million in new equity with $4 million converted from SAFEs. That earlier money was earmarked for commercial expansion, manufacturing scale-up, and platform development.
What's the endgame? Araceli's Endeavor system pairs cellular imaging with real-time analysis to produce the curated datasets used to train and validate drug discovery AI models. The company has partnered with Ginkgo Bioworks, integrating Endeavor into Ginkgo's autonomous lab in Boston.
By the numbers: The $4.5 million figure appears to be the offering target, not cash in hand. A recent SEC filing lists about $2.53 million sold so far.
The signal: The raise sits in the upper tier of recent biotech financings by size, landing in roughly the 81st percentile. For an equipment maker leaning into AI-driven drug discovery, the follow-on round reads as a bet that demand for data to feed those models is still climbing.
Read more: bizjournals.com
Image credit: Generated with Gemini
